Source: Palmieri D, Lockman PR, et al. Vorinostat Inhibits Brain Metastatic Colonization in a Model of Triple-Negative Breast Cancer and Induces DNA Double-Strand Breaks. Clin Cancer Res. Sept. 29, 2009. Vol.15, No. 19.
Hope and help for triple-negative (TNBC) and other forms of hormone-negative breast cancer.
Source: Palmieri D, Lockman PR, et al. Vorinostat Inhibits Brain Metastatic Colonization in a Model of Triple-Negative Breast Cancer and Induces DNA Double-Strand Breaks. Clin Cancer Res. Sept. 29, 2009. Vol.15, No. 19.
Researchers studied four genetically different cancer types, including triple negative, and determined that the drug combination eliminated existing tumors and prevented regrowth; neither drug alone was effective against the cancer cells.
As a result of this tests, clinical trials are being planned on the use of metformin and doxorubicin in women with early stage breast cancer. Enrollment of patients may begin next year.
Source: Hirsch, Heather A., Iliopoulos, Dimitrios, Tsichlis, Philip N., Struhl, Kevin
Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission
Cancer Res 2009 0: 0008-5472.CAN-09-2994
Even though I had estrogen-negative (ER-) breast cancer, my oncologist was insistent that I take tamoxifen. I refused. And I changed oncologists. The research below supports my decision.
Women who took tamoxifen for at least five years had more than a four-fold increased risk of estrogen-receptor negative cancer in the second breast compared to women who were not treated with hormone therapy, according to research published in the journal Cancer Research.
The drug reduced the incidence of estrogen-receptor-positive breast cancer by 60 percent, however.
Researchers studied 367 women with estrogen-receptor-positive cancer that had also spread to the second cancer. The comparison group was 728 women with only a primary cancer.
Some details:
• breast cancer survivors overall who took hormonal therapy were at a reduced risk of second breast cancer.
• use of tamoxifen for at least five years reduced the risk of both estrogen-positive and progesterone-positive breast cancer.
• use of the drug for at least five years led to increased risk of both estrogen-negative and progesterone-negative.
Researchers said that the reason the risk increases with longer exposure is because more time is needed “to foster an environment that promotes estrogen receptor-negative tumor growth.” Essentially, they said, hormone therapy gives hormone--negative cells a growth advantage.
SOURCE: Li, Christopher I., Daling, Janet R., Porter, Peggy L., Tang, Mei-Tzu C., Malone, Kathleen E., “Adjuvant Hormonal Therapy for Breast Cancer and Risk of Hormone Receptor-Specific Subtypes of Contralateral Breast Cancer,” Cancer Research, 2009 0: 0008-5472.CAN-09-1355. Published online August 25, 2009.
As I have mentioned before, alternative treatments have been important to me in my battle with breast cancer—during and after treatment. I have to give a nod to Western medicine—research consistently shows the chemo is especially effective in combating hormone-negative breast cancer, including triple negative. l
But yoga, meditation, acupuncture, and proper diet have been equally important, maybe more so. Here’s what I have done to supplement Western treatments of surgery, chemo, and radiation.
Yoga: I am a late-comer to this wonderful Eastern practice. I began doing yoga after I finished treatment and I try to do it at least four times weekly. Before cancer (BC), I used to love my evening drink—or drinks. I needed them to relax me. No more. One yoga session relaxes me way more than alcohol ever did—and the benefits continue, whereas alcohol-induced relaxation turns to nervousness and sleeplessness. And alcohol is implicated in cancer. So if yoga does nothing more than reduce my drinking, it has provided a serious benefit. But it does much more—it’s kept my body, I think, in shape internally and externally.
Meditation. Closely tied to yoga, meditation calms me, helps me think clearly and focus, makes me sleep better, and in general gives me a flat-out Zen feeling. Ahmmmmmmmmm. I am especially sensitive to noise. Now, after meditation, if I hear a bothersome noise—a neighbor’s stereo, for example—I breathe deeply into the noise and eventually I am calmed.
Acupuncture. My acupuncturist is a wonder. I went to her before each chemotherapy session and she prepared me well and, I believe, reduced my nausea. Now, she has a perceptive link to my health that truly balances me. I can walk into Abby’s office feeling internally whacky and leave feeling truly connected to my health. I have gone to her for allergies, poison ivy, lingering colds, and anything else that has not responded to my normal ministrations. When she listens to my pulse, she hears everything from the fact that I have recently eaten nuts and not chewed them thoroughly enough to the stomach upset I hadn’t yet mentioned. I believe that, if I had a serious health problem, she would be plugged into it before I was.
Proper diet. A low-fat diet rich in vegetables and fruits has been found to be a solid cancer fighter. I start every day with a green drink and, usually, a smoothie with organic yogurt, blueberries, freshly ground flax seeds, and a banana. I end every day with a mixture of freshly juiced carrots, kale, cabbage, parsley and, occasionally, a beet. Throughout the day I get my minimum of five servings of fruits and vegetables and focus on antioxidants (blueberries) and cruciferous cancer-fighters (kale, cabbage, broccoli). I make sure I get enough Vitamin D--preferably through sun, and folic acid through vegetables and supplements.
The benefit to this diet is that my body mass index is at a healthy 23. Before cancer, I was at 29, just a snip under being obese.
Breastcancer.org has a good discussion on complementary and alternative treatments.
American and European chemotherapy treatments use different drugs. So when I read about research done in Italy that showed significant response to a battery of chemo drugs, I was curious. The more I read about the study, though, the more I wondered. Look at the drugs used below. That’s a lot. A whole lot. Still, the response is good. But the toxic reactions are also significant.
Here’s the scoop:
Eight weekly cycles of cisplatin, epirubicin, and paclitaxel (PET) before surgery showed improvement in disease-free survival for women with triple negative breast cancer, in a phase II trial of women studied from 1999 through 2008. All had large ER-, PR-, Her2- tumors.
Seventy-four women received cisplatin (30 mg/m2) , (epirubicin 50 mg/m2), paclitaxel (Taxol) (120 mg/m2), with granulocyte colony-stimulating factor support. Within three weeks of chemo, all had surgery, primarily breast-conserving surgery. Forty-six of the women were in complete remission after surgery.
After that, those with fewer than four affected lymph nodes had combination chemotherapy with cyclophosphamide, methotrexate, and fluorouracil. Those with more than four affected nodes had an additional four cycles of fluorouracil-epirubicin-cyclophosphamide (FEC) (epirubicin instead of methotrexate)
Forty-six of the women had pathologically complete response (pCR)—their cancer was effectively gone—after this regimen.
At 41 months, five-years projected disease-free survival (DFS) was 90 percent for the pCR women. For those without a pCR, the five-year DFS was 57 percent.
The 90 percent number, of course, is great. Still, that’s a lot of chemo. And 31 of the patients had severe neutropenia and anemia. Fewer than 20 percent had severe non-hematological toxicity.
The study was published in the July 2009 Annals of Oncology.
For comparison, in the United States, the current therapy consists of high-doses of cytoxan and adriamycin (AC) every two weeks; taxol is added (ACT) for those with affected lymph nodes. This offers a five-year overall survival rate of 83 percent for hormone-negative and a five-year disease-free survival rate of 73 percent. This research was published in the Journal of the American Mecial Association in 2006.
ACT was also found to improve disease-free survival for triple negative in a study published in the Journal of Oncology in 2009.
If I were looking for insurance right now, I would be largely out of luck. As a breast cancer survivor, I have that nasty pre-existing condition that allows insurers to deny me coverage or charge me so much I cannot afford it. When I turn 65, however, I will be eligible for Medicare, with no restrictions because of previous health problems. I will pay the same as other Medicare recipients for my care. Even Medigap policies—supplemental insurance that covers the 20 percent of health costs not covered by Medicare—cannot discriminate based on pre-existing coverage.
That, to me, is the biggest reason cancer survivors, their families and loved ones should support healthcare reform and should not be afraid of any expansion of government-run plans. At present, government-run healthcare allows us the treatment we need and views us as whole persons rather than pariahs who had the gall to get sick. Insurance companies too often look at us as expensive inconveniences. It is unconscionable that, in America, sick people go broke trying to pay for care or avoid needed treatments because their insurance won’t cover them. This is not the healthcare a great country deserves; it is the healthcare the insurance companies allow us to have.
Among the basic tenets of President Obama’s plan are the necessity of covering pre-existing conditions, protecting families from healthcare-related bankruptcy, and allowing people to maintain coverage if they lose their jobs.
The American Cancer Society supports healthcare reform for these reasons and for another biggee—prevention. The cost of a mammogram can cause a cash-strapped women to avoid caring for her health, which can put her life in jeopardy. In what world is that considered right?
DEATH PANELS
Aurghhhhhhhhh. It’s startling that this idea has gained the traction is has. The healthcare bill as it exists simply states that people have the option of end-of-life counseling. The word option means we can take it or leave it. And this means only things like living wills or an explanation of Hospice care. My husband and I already have living wills—we got them before I even got sick. We do not want to be kept on life support if our lives are essentially over—and we do not want our kids burdened with that decision.
Interestingly, Republicans supported this option in the 2003 Medicare prescription drug bill. Now, they are ranting about pulling the plug on Grandma. Is that politics or principle? Well....
One conservative, however, David Brooks of The New York Times, said, on today’s Meet the Press, "the crazies are attacking the plan because it will cut off granny. That is simply not true, that simply is not going to happen." On Friday, on PBS’s News Hour, Brooks said, “But it's about having serious discussions about care at the end of life. And we're going to have to have those discussions. So, in some weird way, I'm pro-death panel. I want to have those discussions, whether it's one-on-one or just as a society."
Be assured that death panels are not going to come to the chemo ward and tell us we’re all useless and not fit to live. A wise doctor, however, might give us some counseling about how to face the end of life. Death is going to happen to all of us, although most people avoid even thinking about it. Once you’ve had cancer, though, the reality of death is embedded in your consciousness. Still, are we really ready to face it? Do we know what Hospice offers? Do we understand what a living will is and what it means? Have we made provisions that mean we accept the responsibility for what happens at the end of our lives, rather than foisting that on our children or grandchildren?
Healthcare reform, as I see it, is about fairness. I am more invested, I suspect, because of the many people I know struggling with cancer. Fighting the disease is enough. We should not also have to fight our insurance companies. Let's level the playing field and truly give patients the rights they need and deserve.
Scientists have found that one specific cancer antigen—CT-X—is more frequently found in hormone receptor-negative breast cancer than in other types of breast tumors, according to research published online in advance of publication in Proceedings of the National Academy of Sciences.
And this means?
Ultimately, researchers say, vaccines based on CT-X might provide treatment for ER-negative patients.
Whooheee. Keep the research coming. And let's turn it into treatment options.
SOURCE: Anita Grigoriadis, Otavia L. Caballero, Keith S. Hoek, Leonard da Silva, Yao-Tseng Chen, Sandra J. Shin, Achim A. Jungbluth, Lance D. Miller, David Clouston, Jonathan Cebon, Lloyd J. Old, Sunil R. Lakhani, Andrew J. G. Simpson, and A. Munro Neville. "CT-X antigen expression in human breast cancer," Proceedings of the National Academy of Sciences, 2009. www.pnas.org/cgi/doi/10.1073/pnas.0906840106
From the Ludwig Institute for Cancer Research: Vaccine in Clinical Trials Shows Promise in Treating ER-Negative Breast Cancers, Including Triple Negative Breast Cancer:
A comprehensive analysis of nearly 1,600 tumor samples has found that CT-X genes are expressed in nearly half the breast cancers that lack the estrogen receptor (ER). CT-X gene products are the targets of therapeutic cancer vaccines already in phase III clinical trials for lung cancer and melanoma. The study—to be published in the Early Edition of the Proceedings of the National Academy of Sciences this week—was led by the international Ludwig Institute for Cancer Research (LICR). ER negative breast cancers, which account for a third of all breast cancer cases, are a group of tumors that has a generally poor prognosis and few therapy options. A subgroup of the ER negative group is triple-negative breast cancer (TNBC), which lacks the estrogen, progesterone and HER2 receptors. TNBC is responsible for most of the breast cancers that strike down African American and young women.
In the current study, gene and protein expression studies showed that nearly half of primary ER negative and triple-negative breast cancers express members of either or both the MAGEA and NY-ESO-1/CTAG1B families of CT-X genes. Approximately half of the primary tumor samples from patients with the basal-like form of breast cancer, which is usually ER negative, also expressed either or both of these gene families, and nearly two-thirds of metastases from basal-like tumors also expressed these genes.
These findings suggest that a therapeutic vaccine combining members of the two CT-X families could be a new therapy approach to filling a critical unmet need.
Dr. Andrew Simpson, LICR scientific director and an author of the study, said that clinical trials based on the findings of the PNAS study could theoretically be initiated in the near future. "Vaccines targeting MAGEA3 are already in phase III trials, and the Cancer Vaccine Collaborative, a partnership between the Ludwig Institute and the Cancer Research Institute, has demonstrated the safety of different forms of the NY-ESO-1 antigen in phase I and II trials in a variety of tumor types."
According to LICR's Dr. A. Munro Neville, the senior author of the study, obtaining clinic-grade material for more members of the CT-X families and funding for a clinical trial will be the next steps in determining if therapeutic cancer vaccines can meet a critical need in breast cancer therapy.
CT genes—the X denotes chromosome localization—encode CT antigens, proteins that are recognized by the immune system. Spontaneous immune responses against CT antigens are thought to be a natural form of cancer control and might be the mechanism behind spontaneous remission.
Therapeutic cancer vaccines are being developed to induce, strengthen and/or sustain immune responses against cancer. GlaxoSmithKline (GSK), which licensed MAGEA3 and NY-ESO-1 from LICR, is currently conducting phase III clinical trials of a MAGEA3-based cancer vaccine, or "antigen-specific cancer immunotherapy" (ASCI) in non-small cell lung cancer and melanoma.
Source: Ludwig Institute for Cancer Research
A great story here:
For Dr. Lisa Newman, a 16-hour trip over two days from Michigan to Ghana in Africa is just part of the journey in uncovering clues about a rare form of breast cancer.
Newman, a surgical oncologist specializing in breast cancer at the University of Michigan, collaborates with doctors in Kumasi, Ghana, in hopes of discovering the origins of an aggressive and difficult to treat form of breast cancer that disproportionately affects black women. It is called triple negative breast cancer or TNBC.
"The women that are most likely to be afflicted with the triple negative breast cancers are younger aged women, women in the pre-menopausal age range, and women with African ancestry," says Newman.
Read the entire story here.
A study on racial disparities in breast cancer published in the Journal of the National Cancer Institute challenges the assumption that receptor status is the primary reason African-Americans have more agressive forms of breast cancer.
Researchers discovered that black patients with breast cancer had worse survival than white patients, despite identical treatment and follow-up and irrespective of hormone receptor status. They say this shows that African-American women may get a different type of cancer altogether--something that cannot be entirely explained as hormone-receptor negative or triple-negative. And this cancer is highly aggressive. The research also casts doubt on the theory that lower survival rates among African-Americans for certain cancers are due solely to factors such as poverty and poor access to quality health care.
The study used data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program on 244,786 women diagnosed from January 1990 through December 2003 and followed through December 2004.
According to an article from the National Institutes of Health, researchers found that:
...regardless of ER status, black women with breast cancer were still more likely to die of the disease than white women. This disparity remained even when the researchers adjusted for age at diagnosis, stage and grade of the tumor, year of diagnosis, and socioeconomic status. When the researchers examined the hazard rate trends in black and white women, they noticed that the largest differences occurred in the first three years after diagnosis in both ER- and ER+ tumors.
Why do blacks have more aggresive tumors, even allowing for receptor status? Researchers suggest the environment and genetics may both be an issue. The NIH added:
This analysis confirmed that, despite the higher incidence of ER- tumors (which are associated with a less favorable prognosis) among black women, the differences in survival outcomes between the two populations were driven largely by differences in the hazard rate as opposed to differences in estrogen-receptor status.